MLICM
PEAR

Metropolitan Life Insurance Company (MetLife)’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,946
Closed -$5.84K – 2510
2022
Q4 		$5.84K Buy
+4,946
New +$10.4K ﹤0.01% 2351

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PEAR Position: Q1 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q1 2023, closing a stake of 4,946 shares — an estimated $5.84K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PEAR in Q4 2022 and held it in 1 quarter. The position peaked at $5.84K in Q4 2022. 53 funds tracked by Wall St. Rank hold PEAR as of Q1 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 4,946 Pear Therapeutics, Inc. Class A Common Stock shares in Q1 2023, an estimated $5.84K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2022 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Pear Therapeutics, Inc. Class A Common Stock position peaked at $5.84K in Q4 2022.
  • 53 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q1 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2023, filed 15 May 2023.